OH-FORGE-BIOLOGICS
17.5.2022 13:02:11 CEST | Business Wire | Press release
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today the formation of an independent board of preeminent experts, a Scientific and Manufacturing Advisory Board (SMAB), to advise the Company on its gene therapy manufacturing offerings and therapeutics pipeline development. The board will serve the traditional functions of a scientific advisory board, with a distinct and strategic emphasis on manufacturing advancements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005561/en/
“We are thrilled and privileged to have gathered such a renowned group of experts in gene therapy development and manufacturing to work with us to us deliver quality products to our clients, especially as we accelerate AAV production with our new 5,000L bioreactor,” said Timothy J. Miller, Ph.D., CEO, President, and Co-Founder of Forge Biologics. “The board’s guidance will help focus our mission of manufacturing potentially life-saving therapies to patients suffering from genetic diseases.”
Members of Forge’s inaugural Scientific and Manufacturing Advisory Board include:
- Steven J. Gray, Ph.D ., Associate Professor, Department of Pediatrics, University of Texas Southwestern Medical Center. Dr. Gray serves as the director of the UTSW Viral Vector Facility. His core expertise is in adeno-associated viral (AAV) gene therapy vector engineering, followed by optimizing approaches to deliver a gene to the nervous system. His research focus has also been heavily focused in developing AAV-based treatments for neurological diseases, several of which have translated into clinical trials.
- Robert Kotin, Ph.D. , Executive and scientific co-founder at Stealth Newco; Scientific co-founder of Generation Bio and Frontera Therapeutics; Vice President of Production, Voyager Therapeutics. Dr. Kotin is a preeminent expert in AAV gene therapy manufacturing and the co-inventor of the baculovirus-based AAV production system. He joined Voyager from the National Heart, Lung and Blood Institute of the National Institutes of Health, where he served for more than 20 years in roles of increasing responsibility, most recently as Senior Investigator and Laboratory Chief. Previously, Dr. Kotin served as head of the AAV gene therapy program at Genetic Therapy and as Senior Research Scientist of the Medical Research Division at Lederle Laboratories.
- Karen Kozarsky, Ph.D. , Co-Founder and Chief Scientific Officer, SwanBio Therapeutics. Dr. Kozarsky has over 25 years of experience in gene therapy, with a primary focus on the development of gene therapy for inherited rare diseases utilizing AAV vectors. She has been involved in the development of multiple gene therapy products that are in clinical trials. Previously, Dr. Kozarsky was President of Vector BioPartners, Vice President of R&D at REGENXBIO Inc., and Head of Gene Therapy in the GlaxoSmithKline Biopharmaceutical Center of Excellence for Drug Discovery.
- Haiyan Ma, Ph.D. , Director of Science, Northern Biomolecular Services. Dr. Ma is a scientific leader with over 30 years of experience in academic laboratories, pharmaceutical industry, and contracted research. She has a broad background in molecular and cell biology, applications of cell and gene therapy, bioanalysis of DNA/RNA/proteins, and virology. She led the establishment of a GLP compliant molecular biology lab, and served as Study Director or Contributing Scientist in 150+ studies.
- Simon N. Waddington, Ph.D. , Professor of Gene Therapy at University College London. Dr. Waddington’s research has spanned viral and non-viral gene therapy. He has published in Cell , Nature Medicine , and Science Translational Medicine on Adenovirus, AAV and lentivirus biology. Some of the fruits of this work are in late-stage clinical trials.
The board will advise Forge leadership on strategic direction and goals, specifically in the areas of manufacturing and scientific or therapeutic program development.
“The landscape for clinical gene therapy is constantly evolving, and we are eager to work with our board members to ensure that we are observant, thoughtful and agile in our responses to the developments in the field,” said Erandi De Silva, Ph.D., Co-Founder and Senior Vice President of Product Development at Forge. “We are striving to effectively build strategies to overcome the barriers to efficient manufacturing and development in gene therapy, and this group’s guidance will be invaluable.”
About Forge Biologics
Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life-changing gene therapies and help bring them from idea to reality. Forge has a 200,000 square foot facility in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005561/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Spatial Announces Release 2027 1.0 with New Enhancements Across CAD Modeling, Interoperability, Data Preparation, and Meshing17.11.2026 20:10:00 CET | Press release
Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced the availability of its 2027 1.0 Release. This latest release introduces new capabilities and enhancements across Spatial's 3D ACIS Modeler, CGM Modeler, 3D InterOp, Data Prep and CSM/CVM product lines. Designed to improve efficiency, flexibility and robustness across CAD modeling, interoperability, data preparation and simulation workflows, the release delivers enhanced geometry processing, expanded modeling capabilities, improved CAD translation and advances in mesh generation for a better workflow coverage. 3D ACIS Modeler Enhanced Blending (Filleting) The 3D ACIS Modeler introduces support for asymmetric fixed-width blends with a conic cross-section, providing users with finer control over smooth transitions between edges. This enhancement builds on the symmetric fixed-width blend with a conic cross-section capabilit
Global EV Alliance Survey: EV Drivers Identify Myths and Misconceptions as the Biggest Barrier to Adoption17.11.2026 19:00:00 CET | Press release
Myths and misconceptions about electric cars, from battery lifespan and fire risk to grid collapse, are the biggest barrier to EV adoption, according to respondents to the annual Global EV Driver Survey. The 2026 survey draws on responses from more than 29,500 EV drivers across 34 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117539716/en/ MYTHS. Battery lifespan (72%), fire risk (58%) and grid collapse (45%) top the list of EV myths reported by respondents to the 2026 Global EV Driver Survey, which gathered responses from more than 29,500 EV drivers across 34 countries. “The EV transition is not just an infrastructure or affordability challenge. It is also an information challenge. Outdated information and misconceptions continue to influence decisions long after the technology has moved on,” says Ellen Hiep, from the Steering Committee of the Global EV Alliance (GEVA). Myths the greatest barrier Asked to ide
TreeFrog Therapeutics Appoints James Sterling as Chief Financial Officer17.11.2026 18:04:00 CET | Press release
Seasoned biotech CFO with gene therapy, diagnostics, IPO and Wall Street experience joins the executive leadership team TreeFrog Therapeutics, a biotechnology company developing scalable cell therapies built on its proprietary C-Stem™ technology, today announced the appointment of James Sterling as Chief Financial Officer, effective November 1, 2026. James joins TreeFrog’s executive leadership team and reports to Mark Rothera, President and Chief Executive Officer. He oversees finance, investor relations and corporate development as the company enters its next phase of growth. “I am delighted to welcome James to TreeFrog. James brings a valuable combination of biotech CFO and Wall Street experience that supports our ambitions to develop TreeFrog into a key enabling partner and drug developer in the regenerative medicines field,” said Mark Rothera, President and Chief Executive Officer of TreeFrog Therapeutics. James contributes deep experience in corporate finance, capital markets and
Visa Report: AI-Enabled Fraud and Third-Party Attacks Are Scaling Worldwide17.11.2026 16:40:00 CET | Press release
Third-party incidents surged 62%, while Visa Scam Disruption identified more than $1.4 billion in potential fraud Fraud is becoming more automated, targeted and global as criminals use AI to exploit weak points across the payments ecosystem and target third-party providers that can provide access to multiple downstream payment organizations, according to the Visa (NYSE: V) Fall 2026 Biannual Threats Report released today during International Fraud Awareness Week. Developed by Visa Payment Ecosystem Risk and Control (PERC), the report examines threat activity observed between January and June 2026 and finds that AI is not creating entirely new categories of fraud. Instead, it is helping criminals that execute existing attacks faster, at greater scale, and with greater precision, while increasingly targeting third-party providers that can provide access to multiple downstream organizations at once. Although attack volumes increased in several areas, the report also found evidence that co
Sparxity Appoints former Cray CEO Peter Ungaro and Semiconductor Veteran Daniel Armbrust to its Advisory Board17.11.2026 16:00:00 CET | Press release
Appointments bring decades of leadership experience in supercomputing, semiconductor commercialization, and scaling advanced computing business Sparxity, a leader in sparse-native computing, today announced that Peter Ungaro, former President and CEO of Cray, Inc., and Daniel Armbrust, former President and CEO of SEMATECH and co-founder of Silicon Catalyst, have joined its Advisory Board as independent members. Armbrust has been elected Chairman of the Advisory Board and Ungaro Deputy Chairman by their fellow board members. The appointments strengthen the company’s leadership as it scales its sparse-native computing technology for next-generation AI and high-performance computing (HPC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117761685/en/ From left to right, Daniel Armbrust, former President and CEO of SEMATECH and co-founder of Silicon Catalyst and Peter Ungaro, former President and CEO of Cray, Inc. Peter Ungaro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
